Wednesday, August 3, 2022 - 2:16am
World, Motherboard, Atropine, Ageing, State Council, Parent, Eye, Safety, Episode I, Sun, Ministry, Director, Company, Fudan University, S. D. Warren Co. v. Maine Board of Environmental Protection, Eye and ENT Hospital of Fudan University, Control, Research, World Health Organization, Technology, US Foods, Growth, List of education ministries, Education, Business, Adolescence, Food, SEHK, CEO, Board, Ophthalmology, Achievement, FDA, Benjamin, National Health Planning and Resources Development Act, Cover My Eyes (Pain and Heaven), Approximation error, Beijing Tongren Hospital, NDA, CIC, The Company, Hospital, Principal, Hong Kong Stock Exchange, Patient, Overalls, Pharmaceutical industry, Vaccine, Medical imaging, Myopia
The primary objective of the China CHAMP and Mini-CHAMP trials is to evaluate the efficacy and safety of NVK002 for the treatment of myopia progression in children and adolescents.
- The primary objective of the China CHAMP and Mini-CHAMP trials is to evaluate the efficacy and safety of NVK002 for the treatment of myopia progression in children and adolescents.
- These early completions of patient recruitment across both trials, gives the company a strong headstart in moving towards its goal to lead the market in launching a myopia progression treatment drug.
- Following this, a New Drug Application ("NDA") submission to the US Food and Drug Administration (the "FDA") is expected in 2023.
- Dr. Li Xiaoyi (Benjamin), Chairman of the Board of Directors, Executive Director and CEO of Zhaoke Ophthalmology, said, "The early completion of the patient recruitment of NVK002's Phase III clinical trials marks another huge and exciting milestone for Zhaoke Ophthalmology.